EGFR and non-small cell lung carcinoma: Pemetrexed monotherapy has demonstrated moderate efficacy and good safety in chemotherapy-naïve ECOG performance status (PS) 2 patients with EGFR wild-type or unknown advanced non-squamous NSCLC [13].